Valeant’s latest woe isn’t even financial By: MarketWatch July 22, 2016 at 11:35 AM EDT The FDA declined to approve the drug company’s glaucoma eye drop treatment because of manufacturing facility problems. Read More >> Related Stocks: Standard & Poors 500 Valeant Pharmaceuticals International, Inc.